Back to Search
PAUL KURTIN, M.D.
M.D.
Anatomic Pathology & Clinical Pathology Physician
NPI: 1265404602Individual
Specialties, Licenses & Credentials
Clinical Pathology/Laboratory Medicine Physician
Pathology — Clinical Pathology/Laboratory Medicine
Code: 207ZP0105X
32405(MN)
Anatomic Pathology & Clinical Pathology PhysicianPrimary
Pathology — Anatomic Pathology & Clinical Pathology
Code: 207ZP0102X
32405(MN)
Cytopathology Physician
Pathology — Cytopathology
Code: 207ZC0500X
32405(MN)
Research & Publications (20)
Pathologic and clinical features of primary pulmonary extranodal marginal zone B-cell lymphoma of MALT type.
PMID 11474283·Am J Surg Pathol·2001
8-other
Gene expression profiling of pulmonary mucosa-associated lymphoid tissue lymphoma identifies new biologic insights with potential diagnostic and therapeutic applications.
PMID 18974375·Blood·2009
8-other
Spontaneous mutation of hemoglobin Lufkin in a white boy.
PMID 19346882·J Pediatr Hematol Oncol·2009
5-case
The proposed diagnostic criteria change for chronic lymphocytic leukemia: unintended consequences?
PMID 19541837·Blood·2009
8-other
Standardize to excellence: improving the quality and safety of care with clinical pathways.
PMID 19660633·Pediatr Clin North Am·2009
8-other
Neonatal intensive care unit collaboration to decrease hospital-acquired bloodstream infections: from comparative performance reports to improvement networks.
PMID 19660632·Pediatr Clin North Am·2009
8-other
Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas.
PMID 18987657·Leukemia·2009
8-other
Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenström's macroglobulinemia.
PMID 19287458·Mod Pathol·2009
8-other
Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group.
PMID 18569634·Leuk Lymphoma·2008
3-trial
Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group.
PMID 18470909·Cancer·2008
3-trial
Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course.
PMID 18645192·J Clin Oncol·2008
8-other
Predictive value of blood and bone marrow flow cytometry in B-cell lymphoma classification: comparative analysis of flow cytometry and tissue biopsy in 252 patients.
PMID 18613994·Mayo Clin Proc·2008
4-observational
Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group.
PMID 18543327·Cancer·2008
3-trial
Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas.
PMID 18401419·Leukemia·2008
8-other
The prevalence of IG translocations and 7q32 deletions in splenic marginal zone lymphoma.
PMID 17989713·Leukemia·2008
8-other
Incidence of TCR and TCL1 gene translocations and isochromosome 7q in peripheral T-cell lymphomas using fluorescence in situ hybridization.
PMID 18628085·Am J Clin Pathol·2008
8-other
Subcutaneous interleukin-4 (IL-4) for relapsed and resistant non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group, NCCTG 91-78-51.
PMID 17613756·Leuk Lymphoma·2007
3-trial
Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.
PMID 17582068·N Engl J Med·2007
8-other
Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications.
PMID 16840723·Blood·2007
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 200 1ST ST SW
ROCHESTER, MN 55905 - Phone
- (507) 284-2511
Quick Facts
- NPI
- 1265404602
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 3
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile